Clinical

Dataset Information

0

Full Spectrum Endoscopy (FUSE) colonoscopy versus conventional forward-viewing colonoscopy in the detection of dysplasia in patients with chronic inflammatory bowel diseases .


ABSTRACT: Interventions: Randomized order of colonoscopy type (conventional versus FUSE colonoscopy) to determine the miss rates of colonoscopy type. The intervention is the use of the FUSE colonoscope which is a colonoscope that incorporates 3 cameras on the colonoscope tip to provide a panoramic 330-degree field of view. .The size and function of the FUSE colonoscope is otherwise the same as the conventional colonoscope (control). Both instruments visualise the internal lining of the bowel and permit the identification and removal of neoplasia. All subjects will have both procedures performed back-to-back (crossover tandem colonoscopy) but the order of the procedure will be randomized. The effect is that the second procedure will determine if lesions were missed during the first procedure, and which colonoscope can identify more neoplasia. Both colonoscopies are expected to be equivalent in duration, taking 15-25 minutes. Quality indicator is that colonoscopy withdrawal should be of at least 6 minutes to improve the chances of not missing pathology. Both colonoscopies are conducted by investigators who are experienced in surveillance colonoscopies and accredited endoscopists. The histopathologists are from the Department of Pathology and familiar with the identification and interpretation of IBD dysplasia. Where dysplasia is found, a second gastrointestinal pathologist will assist with the grading through consensus. Both pathologists are blinded to the order of the colonoscopy (which is coded). There is no need for a wash out, as this is not a drug trial. The second colonoscopy is inserted as soon as the processor is connected and switched on, which usually takes 4-5 minutes. The patient remains under sedation during the intervening period and we wish to keep that as brief a Primary outcome(s): Dysplasia miss rates on a per-lesion analysis [Following completion of both colonoscopies and histological confirmation of the lesions removed during the procedures. ] Study Design: Purpose: Diagnosis; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Crossover;Type of endpoint: Safety/efficacy

DISEASE(S): Inflammatory Bowel Diseases,Oral And Gastrointestinal-inflammatory Bowel Disease,Colorectal Cancer,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)

PROVIDER: 2463098 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2466130 | ecrin-mdr-crc
| 2455846 | ecrin-mdr-crc
2015-03-28 | MSV000079088 | MassIVE
2013-10-01 | E-MEXP-3756 | biostudies-arrayexpress
| 2463444 | ecrin-mdr-crc
| EGAS00001005947 | EGA
| PRJNA319957 | ENA
| 27940 | ecrin-mdr-crc
2023-08-07 | GSE154548 | GEO
| 2370635 | ecrin-mdr-crc